122 related articles for article (PubMed ID: 38152740)
1. Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis.
And Biomechanics AB
Appl Bionics Biomech; 2023; 2023():9813798. PubMed ID: 38152740
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis.
Yao M; Cheng S; Zhai X; Zhao H; Hong J; Li X; Meng Y; Chen W
Appl Bionics Biomech; 2022; 2022():9084852. PubMed ID: 36091626
[TBL] [Abstract][Full Text] [Related]
3. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
4. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma-A Propensity Score Weighted Comparison of Efficacy and Safety.
Savic LJ; Chen E; Nezami N; Murali N; Hamm CA; Wang C; Lin M; Schlachter T; Hong K; Georgiades C; Chapiro J; Laage Gaupp FM
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497329
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
6. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
Lin XJ; Li QJ; Lao XM; Yang H; Li SP
BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
[TBL] [Abstract][Full Text] [Related]
7. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
8. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching.
Golfieri R; Bezzi M; Verset G; Fucilli F; Mosconi C; Cappelli A; Paccapelo A; Lucatelli P; Magand N; Rode A; De Baere T
Liver Cancer; 2021 Sep; 10(5):522-534. PubMed ID: 34721513
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.
Kudo M; Ueshima K; Chan S; Minami T; Chishina H; Aoki T; Takita M; Hagiwara S; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Wada Y; Ikeda M; Ishii H; Izumi N; Nishida N
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370183
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma.
Chen S; Yu W; Zhang K; Liu W; Chen C
Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.
Shimose S; Tanaka M; Iwamoto H; Niizeki T; Shirono T; Aino H; Noda Y; Kamachi N; Okamura S; Nakano M; Kuromatsu R; Kawaguchi T; Kawaguchi A; Koga H; Yokokura Y; Torimura T
Hepatol Res; 2019 Aug; 49(8):919-928. PubMed ID: 30969006
[TBL] [Abstract][Full Text] [Related]
12. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
13. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study.
Morishita A; Tani J; Nomura T; Takuma K; Nakahara M; Oura K; Tadokoro T; Fujita K; Shi T; Yamana H; Matsui T; Takata T; Sanomura T; Nishiyama Y; Himoto T; Tomonari T; Moriya A; Senoo T; Takaguchi K; Masaki T
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572832
[TBL] [Abstract][Full Text] [Related]
16. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
Yang B; Liang J; Qu Z; Yang F; Liao Z; Gou H
PLoS One; 2020; 15(2):e0227475. PubMed ID: 32074102
[TBL] [Abstract][Full Text] [Related]
17. Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score.
Zhu ZY; Yuan M; Yang PP; Xie B; Wei JZ; Qin ZQ; Qian Z; Wang ZY; Fan LF; Qian JY; Tan YL
World J Surg Oncol; 2022 Jun; 20(1):192. PubMed ID: 35689233
[TBL] [Abstract][Full Text] [Related]
18. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
19. Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis.
Mosconi C; Gramenzi A; Biselli M; Cappelli A; Bruno A; De Benedittis C; Cucchetti A; Modestino F; Peta G; Bianchi G; Trevisani F; Golfieri R
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1015-1024. PubMed ID: 32236670
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.
Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
J Hepatocell Carcinoma; 2022; 9():685-694. PubMed ID: 35937909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
